VC
PHAT icon

VarCov Co’s Phathom Pharmaceuticals PHAT Stock Holding History

VarCov Co’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,173
Closed -$435K – 507
2026
Q1 		$435K Sell
39,173
-47,586
-55% -$601K 0.16% 237
2025
Q4 		$1.44M Buy
+86,759
New +$1.24M 0.57% 26

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

VarCov Co's PHAT Position: Q2 2026 in Review

VarCov Co sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 39,173 shares — an estimated $435K sold.

VarCov Co first reported a position in PHAT in Q4 2025 and held it in 2 quarters. The position peaked at $1.44M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • VarCov Co reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • VarCov Co sold 39,173 Phathom Pharmaceuticals shares in Q2 2026, an estimated $435K.
  • VarCov Co first reported a position in Phathom Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • VarCov Co's Phathom Pharmaceuticals position peaked at $1.44M in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.